Metabolomics to Predict Acute Kidney Injury in Cirrhosis

Abstract

Patients with cirrhosis have a high risk of developing acute kidney injury (AKI), which is associated with a poor short-term survival and a high healthcare burden (1). Almost half of inpatients develop AKI during hospitalization and nearly 20% of AKI episodes are nosocomial(2). It is well known that AKI in most patients with cirrhosis is related to the underlying circulatory dysfunction due to splanchnic arterial vasodilation, reduction of effecting circulating volume, and renal hypoperfusion(1).